Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
暂无分享,去创建一个
N. Foster | A. Venook | H. Kennecke | D. Niedzwiecki | E. Wolin | P. Kunz | M. Kulke | B. Fruth